Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
46 pending office actions • 24 art units • 39 examiners • 0 of 46 (0%) have an AI response strategy ready • 43 patents granted in the last 365 days
Chugai Seiyaku Kabushiki Kaisha operates within the Biotechnology & Pharmaceuticals technology area with a total of 47 pending office actions. These 47 pending office actions are distributed across 24 distinct art units. This distribution shows that the number of pending actions is higher than the number of 24 distinct art units involved in the prosecution process. The company interacts with 40 distinct examiners to manage these filings.
The busiest examiner identified in the data is MIDDLETON, DANAYA L, who is currently handling 3 busiest examiner pending office actions. These 3 busiest examiner pending office actions are a subset of the total pending office actions currently active for the company. The 40 distinct examiners assigned to the portfolio are more numerous than the 24 distinct art units where the cases are being reviewed. This indicates that many art units contain multiple examiners working on the company's matters.
Practitioners should note that MIDDLETON, DANAYA L manages 3 busiest examiner pending office actions, while the other actions are spread among the other distinct examiners. The Biotechnology & Pharmaceuticals technology area serves as the primary classification for this work. With 40 distinct examiners, the portfolio shows engagement with the patent office staff across the various art units identified in the data.
Based on the USPTO statutory response window for each pending office action. 13 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 13 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (4%) |
| §103 only | 7 (15%) |
| §102 only | 1 (2%) |
| §112 only | 14 (30%) |
| Double-patenting only | 2 (4%) |
| Double-patenting + other | 6 (13%) |
| Multi-statute (no §101) | 14 (30%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MIDDLETON, DANAYA L | 3 | 48.5% | +49.4% |
| SANG, HONG | 3 | 55.0% | +62.4% |
| HABTE, KAHSAY | 2 | 85.0% | +7.4% |
| LANDSMAN, ROBERT S | 2 | 81.3% | +13.0% |
| RYAN, DOUGLAS CHARLES | 2 | 39.2% | +47.6% |
| MOYER, DALE S | 1 | 81.6% | +16.3% |
| VOLKOV, ALEXANDER ALEXANDROVIC | 1 | 29.5% | +21.5% |
| GEMBEH, SHIRLEY V | 1 | 63.2% | +34.0% |
| KIEFER, DALTON EDWARD | 1 | 83.3% | +0.0% |
| CHEONG, CHEOM-GIL | 1 | 64.2% | +52.6% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18726155 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | HABTE, KAHSAY | — |
| 18724369 | POLYPEPTIDE AND METHOD FOR PRODUCING AMINO ACID USING SAME | KIEFER, DALTON EDWARD | — |
| 18595973 | ANTI-HLA-DQ2.5/8 ANTIBODY AND ITS USE FOR THE TREATMENT OF CELIAC DISEASE | LANDSMAN, ROBERT S | — |
| 18579949 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | HABTE, KAHSAY | — |
| 18289627 | ANTI-DDR2 ANTIBODIES AND USES THEREOF | LANDSMAN, ROBERT S | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18266665 | METHOD FOR MEASURING RELATIVE fu RATIO BY DYNAMIC ANALYSIS | NGUYEN, NAM P | 44d overdue |
| 18458292 | THERAPEUTIC AGENT FOR CANCER OF PATIENT WITH DECREASE IN RB1 FUNCTION USING MYT1 INHIBITOR AND CHEMOTHERAPEUTIC AGENT IN COMBINATION, AND TREATMENT METHOD THEREOF | WILLIS, DOUGLAS M | 9d overdue |
| 17417822 | MUTATED tRNA FOR CODON EXPANSION | RYAN, DOUGLAS CHARLES | 3d overdue |
| 17616421 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, PROGRAM, AND METHOD FOR PRODUCING ANTIGEN-BINDING MOLECULE OR PROTEIN | PLAYER, ROBERT AUSTIN | 27d |
| 17766280 | INHIBITOR OF CELL PROLIFERATION IN OBINUTUZUMAB RESISTANT CD20-POSITIVE CANCER, AND MEDICINAL COMPOSITION, MEDICINE, PRODUCTION, METHOD FOR INHIBITING CELL PROLIFERATION, THERAPEUTIC METHOD, TYPE II ANTI-CD20 ANTIBODY, COMPOUNDS, COMBINATION OF SAME, ENHANCER AND INDUCER, EACH RELATING THERETO | SANG, HONG | 29d |
| 19136138 | ROBOT SYSTEM | MOYER, DALE S | — |
| 19091939 | PROTEIN PURIFICATION WITH PROTEIN L | VOLKOV, ALEXANDER ALEXANDROVIC | — |
| 18695400 | COMPOUND HAVING PHOTOCLEAVABLE MOIETY, CONJUGATE, AND SCREENING METHOD USING SAME | BUNKER, AMY M | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17144342 | ANTIGEN-BINDING MOLECULE FOR ELIMINATING AGGREGATED ANTIGENS | SANG, HONG | 53d overdue |
| 17417822 | MUTATED tRNA FOR CODON EXPANSION | RYAN, DOUGLAS CHARLES | 3d overdue |
| 17766280 | INHIBITOR OF CELL PROLIFERATION IN OBINUTUZUMAB RESISTANT CD20-POSITIVE CANCER, AND MEDICINAL COMPOSITION, MEDICINE, PRODUCTION, METHOD FOR INHIBITING CELL PROLIFERATION, THERAPEUTIC METHOD, TYPE II ANTI-CD20 ANTIBODY, COMPOUNDS, COMBINATION OF SAME, ENHANCER AND INDUCER, EACH RELATING THERETO | SANG, HONG | 29d |
| 18394091 | ANTIGEN-BINDING MOLECULE AND COMBINATION | RYAN, DOUGLAS CHARLES | 40d |
| 19136138 | ROBOT SYSTEM | MOYER, DALE S | — |
| 19091939 | PROTEIN PURIFICATION WITH PROTEIN L | VOLKOV, ALEXANDER ALEXANDROVIC | — |
| 18827277 | AMORPHOUS FORM OF TETRACYCLIC COMPOUND | GEMBEH, SHIRLEY V | — |
| 18672417 | POLYPEPTIDE INCLUDING ANTIGEN-BINDING DOMAIN AND CARRYING SECTION | CHEONG, CHEOM-GIL | — |
| Art Unit | Apps |
|---|---|
| 1641 | 5 |
| 1624 | 3 |
| 1675 | 3 |
| 1654 | 3 |
| 1647 | 2 |
| 1635 | 2 |
| 1678 | 2 |
| 1674 | 2 |
| 1643 | 2 |
| 1646 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19136138 | ROBOT SYSTEM | MOYER, DALE S | — | §102§103 | Non-Final OA | — | Pending | Jun 05, 2025 |
| 19091939 | PROTEIN PURIFICATION WITH PROTEIN L | VOLKOV, ALEXANDER ALEXANDROVIC | — | §102§103 | Non-Final OA | — | Pending | Mar 27, 2025 |
| 18827277 | AMORPHOUS FORM OF TETRACYCLIC COMPOUND | GEMBEH, SHIRLEY V | — | §103DP | Non-Final OA | — | Pending | Sep 06, 2024 |
| 18726155 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING NRF2 ACTIVATION EFFECT | HABTE, KAHSAY | 1624 | DP | Non-Final OA | — | Pending | Jul 02, 2024 |
| 18724369 | POLYPEPTIDE AND METHOD FOR PRODUCING AMINO ACID USING SAME | KIEFER, DALTON EDWARD | 1652 | §112 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18672417 | POLYPEPTIDE INCLUDING ANTIGEN-BINDING DOMAIN AND CARRYING SECTION | CHEONG, CHEOM-GIL | 1645 | §103DP | Non-Final OA | — | Pending | May 23, 2024 |
| 18656920 | COMPOSITION COMPRISING TETRACYCLIC COMPOUND | RAMACHANDRAN, UMAMAHESWARI | 1627 | DP | Non-Final OA | — | Pending | May 07, 2024 |
| 18699488 | COMPOSITION INCLUDING PEPTIDE COMPOUND AND SURFACTANT | MIKNIS, ZACHARY J | — | §103§112DP | Non-Final OA | — | Pending | Apr 08, 2024 |
| 18695400 | COMPOUND HAVING PHOTOCLEAVABLE MOIETY, CONJUGATE, AND SCREENING METHOD USING SAME | BUNKER, AMY M | 1625 | §102§103§112 | Non-Final OA | — | Pending | Mar 26, 2024 |
| 18595973 | ANTI-HLA-DQ2.5/8 ANTIBODY AND ITS USE FOR THE TREATMENT OF CELIAC DISEASE | LANDSMAN, ROBERT S | 1647 | §112 | Non-Final OA | — | Pending | Mar 05, 2024 |
| 18580385 | PROTEASE-MEDIATED TARGET SPECIFIC CYTOKINE DELIVERY USING FUSION POLYPEPTIDE | MIDDLETON, DANAYA L | — | §102§112DP | Non-Final OA | — | Pending | Jan 18, 2024 |
| 18579949 | METHOD FOR PRODUCING ARYLAMIDE DERIVATIVE | HABTE, KAHSAY | 1624 | §112 | Non-Final OA | — | Pending | Jan 17, 2024 |
| 18394091 | ANTIGEN-BINDING MOLECULE AND COMBINATION | RYAN, DOUGLAS CHARLES | 1635 | §112 | Final Rejection | 40d | Pending | Dec 22, 2023 |
| 18535310 | CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | SANG, HONG | — | §102§103§112 | Non-Final OA | — | Pending | Dec 11, 2023 |
| 18567432 | METHOD FOR PRODUCING DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHEN, PO-CHIH | 1621 | §112 | Non-Final OA | — | Pending | Dec 06, 2023 |
| 18289627 | ANTI-DDR2 ANTIBODIES AND USES THEREOF | LANDSMAN, ROBERT S | 1647 | §103 | Non-Final OA | — | Pending | Nov 06, 2023 |
| 18286471 | ANTI-C1s ANTIBODY | XIAO, YAN | 1642 | §112 | Non-Final OA | — | Pending | Oct 11, 2023 |
| 18458292 | THERAPEUTIC AGENT FOR CANCER OF PATIENT WITH DECREASE IN RB1 FUNCTION USING MYT1 INHIBITOR AND CHEMOTHERAPEUTIC AGENT IN COMBINATION, AND TREATMENT METHOD THEREOF | WILLIS, DOUGLAS M | 1624 | §103§112 | Final Rejection | 9d overdue | Pending | Aug 30, 2023 |
| 18270793 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | BAHTA, MEDHANIT W | 1692 | §102§103 | Non-Final OA | — | Pending | Jul 03, 2023 |
| 18269099 | ANTIGEN-BINDING MOLECULES WITH IMPROVED CYTOSOL-PENETRATING ACTIVITY | MACFARLANE, STACEY NEE | 1675 | §112 | Non-Final OA | — | Pending | Jun 22, 2023 |
| 18268399 | MEDICINE PRODUCTION METHOD INCLUDING STEP OF FREEZE-DRYING WITH MIXED SOLVENT | BEANE, RANDALL L | 1654 | §102§103§112 | Non-Final OA | — | Pending | Jun 20, 2023 |
| 18268470 | METHOD FOR SCREENING FOR CANDIDATE MOLECULE CAPABLE OF FORMING COMPLEX IN CONJUNCTION WITH PLURALITY OF TARGET MOLECULES | PHAM, KHAI QUYNH TIEN | 1684 | §102§103 | Final Rejection | — | Pending | Jun 20, 2023 |
| 18266665 | METHOD FOR MEASURING RELATIVE fu RATIO BY DYNAMIC ANALYSIS | NGUYEN, NAM P | 1678 | §102§103 | Final Rejection | 44d overdue | Pending | Jun 12, 2023 |
| 18250507 | SYRINGE | IGEL JR, MARK ALAN | 3783 | §103 | Final Rejection | — | Pending | Apr 25, 2023 |
| 18298743 | METHOD FOR ALTERING PLASMA RETENTION AND IMMUNOGENICITY OF ANTIGEN-BINDING MOLECULE | HUYNH, PHUONG N | 1641 | §112 | Non-Final OA | — | Pending | Apr 11, 2023 |
| 18023038 | HETERODIMER FC POLYPEPTIDE | MIDDLETON, DANAYA L | 1674 | §101§102§112DP | Final Rejection | — | Pending | Feb 24, 2023 |
| 18022342 | HETERODIMER FC POLYPEPTIDE | MIDDLETON, DANAYA L | 1674 | §102§112DP | Final Rejection | — | Pending | Feb 21, 2023 |
| 18018460 | METHOD FOR MEASURING PHARMACOKINETICS OF AGENT LABELED WITH NON-RADIOACTIVE SUBSTANCE | XU, XIAOYUN | 1797 | §103 | Final Rejection | — | Pending | Jan 27, 2023 |
| 18157320 | ANTI-C5 ANTIBODIES AND METHODS OF USE | DIBRINO, MARIANNE | 1641 | §102§112Other | Non-Final OA | — | Pending | Jan 20, 2023 |
| 17992032 | METHOD FOR SEARCHING AND SCREENING FOR TARGET OF ANTI-CANCER AGENT USING NON-HUMAN ANIMAL MODEL HAVING NOG ESTABLISHED CANCER CELL LINE TRANSPLANTED THEREIN | BEHARRY, ZANNA MARIA | 1632 | §103 | Non-Final OA | 91d overdue | Pending | Nov 22, 2022 |
| 17954477 | PHARMACEUTICAL COMPOSITION | DENT, ALANA HARRIS | 1643 | §103 | Non-Final OA | — | Pending | Sep 28, 2022 |
| 17914432 | METHOD FOR PRODUCING MULTISPECIFIC ANTIGEN-BINDING MOLECULES | BRISTOL, LYNN ANNE | 1643 | §112 | Non-Final OA | 9d overdue | Pending | Sep 26, 2022 |
| 17798686 | ANTI-CD137 ANTIGEN-BINDING MOLECULE FOR USE IN CANCER TREATMENT | DONOGHUE, BRITTNEY ERIN | 1675 | §103§112DP | Non-Final OA | — | Pending | Aug 10, 2022 |
| 17797540 | METHODS FOR PRODUCING AND/OR ENRICHING RECOMBINANT ANTIGEN-BINDING MOLECULES | ROONEY, NORA MAUREEN | 1641 | §112 | Final Rejection | 28d overdue | Pending | Aug 04, 2022 |
| 17788506 | METHOD FOR SYNTHESIZING PEPTIDE COMPOUND | REYNOLDS, FRED H | 1658 | §103 | Non-Final OA | 44d overdue | Pending | Jun 23, 2022 |
| 17773733 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | SABILA, MERCY HELLEN | 1654 | §112 | Final Rejection | 20d | Pending | May 02, 2022 |
| 17766280 | INHIBITOR OF CELL PROLIFERATION IN OBINUTUZUMAB RESISTANT CD20-POSITIVE CANCER, AND MEDICINAL COMPOSITION, MEDICINE, PRODUCTION, METHOD FOR INHIBITING CELL PROLIFERATION, THERAPEUTIC METHOD, TYPE II ANTI-CD20 ANTIBODY, COMPOUNDS, COMBINATION OF SAME, ENHANCER AND INDUCER, EACH RELATING THERETO | SANG, HONG | 1646 | §102§103§112 | Final Rejection | 29d | Pending | Apr 04, 2022 |
| 17587465 | MOLECULE SPECIFICALLY ACTING IN A TISSUE WHERE A CELL DEATH IS BEING OBSERVED | PATTERSON, SARAH COOPER | 1675 | §112 | Final Rejection | — | Pending | Jan 28, 2022 |
| 17625868 | ANTI-MUTATION TYPE FGFR3 ANTIBODY AND USE THEREFOR | CUNNINGCHEN, KATHLEEN MARY | 1600 | §103§112 | Non-Final OA | — | Pending | Jan 10, 2022 |
| 17621746 | ANTIGEN BINDING MOLECULES THAT BIND PDGF-B AND PDGF-D AND USES THEREOF | HOPKINS, SAMANTHA LAKE | 1641 | §103 | Non-Final OA | 62d | Pending | Dec 22, 2021 |
| 17616421 | INFORMATION PROCESSING SYSTEM, INFORMATION PROCESSING METHOD, PROGRAM, AND METHOD FOR PRODUCING ANTIGEN-BINDING MOLECULE OR PROTEIN | PLAYER, ROBERT AUSTIN | 1686 | §101§103§112 | Final Rejection | 27d | Pending | Dec 03, 2021 |
| 17437448 | ANTI-IL-6 RECEPTOR ANTIBODY-CONTAINING INHIBITOR FOR INHIBITING DETERIORATION OF BBB FUNCTION | DAHLE, CHUN WU | 1641 | §103§112 | Non-Final OA | — | Pending | Sep 09, 2021 |
| 17417822 | MUTATED tRNA FOR CODON EXPANSION | RYAN, DOUGLAS CHARLES | 1635 | §102§103§112 | Final Rejection | 3d overdue | Pending | Jun 24, 2021 |
| 17266029 | METHOD FOR CULTURING CANCER TISSUE OR TISSUE ANALOGOUS TO CANCER TISSUE | IVICH, FERNANDO NMN | 1678 | §102 | Final Rejection | — | Pending | Feb 04, 2021 |
| 17144342 | ANTIGEN-BINDING MOLECULE FOR ELIMINATING AGGREGATED ANTIGENS | SANG, HONG | 1646 | §112 | Final Rejection | 53d overdue | Pending | Jan 08, 2021 |
| 16081522 | PRODUCTION METHOD FOR NONCYCLIC PEPTIDE-NUCLEIC ACID COMPLEX HAVING, AT N-TERMINAL, AMINO ACID WITH THIOL GROUP NEAR AMINO GROUP, LIBRARY THEREOF, AND CYCLIC PEPTIDE-NUCLEIC ACID COMPLEX LIBRARY DERIVED FROM SAME | AUDET, MAURY A | 1654 | §112 | Final Rejection | — | Pending | Jul 08, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial